The aims of treatment for chronic myeloid leukemia (CML) have changed in recent years, as explained here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. With the introduction of tyrosine kinase inhibitors, overall survival has greatly improved. Prof. Saussele highlights the ultimate goal of CML treatment currently as treatment-free remission, and raising the number of patients who can acheive this. This interview took place at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.
